Credit Suisse analyst Martin Auster maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $17.00. The company’s shares closed last Tuesday at $9.40.
According to TipRanks.com, Auster is a 5-star analyst with an average return of 20.8% and a 52.5% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.
Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.60, a 128.0% upside from current levels. In a report issued on March 31, Northland Securities also assigned a Buy rating to the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Based on Flexion Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $26.31 million and GAAP net loss of $19.65 million. In comparison, last year the company earned revenue of $23.65 million and had a GAAP net loss of $33.52 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FLXN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.
